Sunday, August 29, 2021 3:22:35 PM
boi, in general, I … (author’s comments have been deleted).
As to the specific remarks (though some of your #'s are absent):
1) See frrol’s second point:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165674753
2) The initial announcement stated that the trial would be international in scope. Yet, it wasn’t until 50% enrollment was reached in Australia that other countries were “open for business.” I find that strange.
3) If you want to be like Biden, it is “C’mon, man.” Anyway, you nor anyone other than Dr. M and a few others know if a peek occurred. You are speculating like me; Dr. M said Anavex would be able to take a peek, thus, it is not 100% certainty, it hasn’t.
4) There is no argument, except from you, that waiting 18 months, more sufferers are going to deteriorate to such a point, that Blarcamesine will not help them. If the data were strong from the “peek,” then the regulatory agency that need more proof can dictate a P4 (open label, maybe) be conducted with the final results from the P3, but, at least, the product would be available for purchase by those who need it. [IMO, the data from the first 225 will be very strong and persuasive!]
5) C’mon, man! The trial numbers for the first 225 are set and ready for analysis (as well, as another 100 or so who have completed the trial since February, but should be in included in the “peek”). Plus, when the 75 placebo “victims” are analyzed in the OLE, there will be definitive results showing Blarcamesine’s strength.
6) I am not the one who is claiming an interim look will taint the numbers, so I don’t need to do any research. That job belongs to the claimant(s) to prove this fact. Investor points out in post #328048
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165674217
but, I claim the need to address AD’s mortality is as urgent as oncology’s if 18 months must be tacked on. During those 18 month, 900,000 American sufferers will die (using 10 years AD cycle); another 6 million in ROW, while the same numbers deteriorate to a point that they are not going find relief with Blarcamesine.
Another group that would benefit from a "peek," are the caretakers. They will start to have some relief from their exhausting job, too, especially, if the sufferers are able to go to the bathroom on their own.
Peace, boi, ... and BTW, you are no Bio!
Powerwalker
ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
As to the specific remarks (though some of your #'s are absent):
1) See frrol’s second point:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165674753
2) The initial announcement stated that the trial would be international in scope. Yet, it wasn’t until 50% enrollment was reached in Australia that other countries were “open for business.” I find that strange.
3) If you want to be like Biden, it is “C’mon, man.” Anyway, you nor anyone other than Dr. M and a few others know if a peek occurred. You are speculating like me; Dr. M said Anavex would be able to take a peek, thus, it is not 100% certainty, it hasn’t.
4) There is no argument, except from you, that waiting 18 months, more sufferers are going to deteriorate to such a point, that Blarcamesine will not help them. If the data were strong from the “peek,” then the regulatory agency that need more proof can dictate a P4 (open label, maybe) be conducted with the final results from the P3, but, at least, the product would be available for purchase by those who need it. [IMO, the data from the first 225 will be very strong and persuasive!]
5) C’mon, man! The trial numbers for the first 225 are set and ready for analysis (as well, as another 100 or so who have completed the trial since February, but should be in included in the “peek”). Plus, when the 75 placebo “victims” are analyzed in the OLE, there will be definitive results showing Blarcamesine’s strength.
6) I am not the one who is claiming an interim look will taint the numbers, so I don’t need to do any research. That job belongs to the claimant(s) to prove this fact. Investor points out in post #328048
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165674217
but, I claim the need to address AD’s mortality is as urgent as oncology’s if 18 months must be tacked on. During those 18 month, 900,000 American sufferers will die (using 10 years AD cycle); another 6 million in ROW, while the same numbers deteriorate to a point that they are not going find relief with Blarcamesine.
Another group that would benefit from a "peek," are the caretakers. They will start to have some relief from their exhausting job, too, especially, if the sufferers are able to go to the bathroom on their own.
Peace, boi, ... and BTW, you are no Bio!
Powerwalker
ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
